Biotinylated Human CD160 Protein
Catalog No: CD160-HB001
- Species
- Human
- Expression System
- HEK293
- Tag
- His, Avi
- Activity
- Activity verified
Product overview
Recombinant Biotinylated Human CD160 Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Gly25-Leu158 (UniProt accession: O95971-1).
Product Details
- Molecular Aliases
- CD160; BY55; BY55FLJ46513; NK1; NK28
- Protein Length
- Gly25-Leu158
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 17.7 kDa. Due to glycosylation, the protein migrates to 25-35 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Biotinylated Human CD160 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Biotinylated Human CD160 is greater than 95% as determined by SEC-HPLC.
Human HVEM, hFc Tag captured on CM5 Chip via Protein A can bind Biotinylated Human CD160, His Tag with an affinity constant of 0.72 μM as determined in SPR assay (Biacore T200) (QC Test).
Background
CD160 (also Natural killer cell receptor BY55) is a 27 ‑ 30 kDa member of the Ig superfamily. In human, it is expressed principally on nonmyeloid hematopoietic cells. CD160 antigenis a receptor on immune cells capable to deliver stimulatory or inhibitory signals that regulate cell activation and differentiation. Exists as a GPI-anchored and as a transmembrane form, each likely initiating distinct signaling pathways via phosphoinositol 3-kinase in activated NK cells and via LCK and CD247/CD3 zeta chain in activated T cells.
References
- Chabot S, Jabrane-Ferrat N, Bigot K, et al. A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor[J]. Journal of Experimental Medicine, 2011, 208(5):973-986.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.